Evaluation of triblock copolymeric micelles of δ- valerolactone and poly (ethylene glycol) as a competent vector for doxorubicin delivery against cancer

Journal of Nanobiotechnology

Volumn 9, Issue , 2011, Pages

  Nair K, Lekha ^a   Jagadeeshan, Sankar ^a   Nair, S Asha ^a   Kumar, G S Vinod ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIPHILIC COPOLYMERS; AMPHIPHILICS; ANNEXINS; ANTI-TUMOR EFFICACY; ANTI-TUMORS; BIODISTRIBUTIONS; BIOLOGICAL EVALUATION; BLOCK COPOLYMER MICELLES; CANCER CHEMOTHERAPY; CELL LINES; CELLULAR UPTAKE; CORE SHELL STRUCTURE; CYTOTOXIC; DOXORUBICIN; EMULSION METHOD; ENCAPSULATION EFFICIENCY; GLIOBLASTOMAS; IN-VITRO; IN-VIVO; MCF-7 CELLS; MEAN DIAMETER; NANOCARRIERS; PH-DEPENDENT; PHASE ARREST; PROTON NMR; SMALL SIZE; THERAPEUTIC POTENTIALS; TRIBLOCKS; TUMOR SUPPRESSION;

BIODEGRADATION; BLOCK COPOLYMERS; CARRIER CONCENTRATION; CELL CULTURE; CELL DEATH; CHEMOTHERAPY; COPOLYMERIZATION; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; DISEASES; EMULSIFICATION; ENCAPSULATION; ENZYME INHIBITION; ETHYLENE; FLOW CYTOMETRY; FLUORESCENCE; GLYCOLS; MICELLES; POLYETHYLENE GLYCOLS; RATING; RING OPENING POLYMERIZATION;

CONTROLLED DRUG DELIVERY;

DELTA VALEROLACTONE; DOXORUBICIN; LACTONE DERIVATIVE; MACROGOL; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DELTA-VALEROLACTONE; DRUG CARRIER; LIPOCORTIN 5; MACROGOL DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYMER; PYRONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CLINICAL EVALUATION; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG STRUCTURE; ENCAPSULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MICELLE; PH; POLYMERIZATION; SYNTHESIS; CHEMISTRY; EVALUATION; G2 PHASE CELL CYCLE CHECKPOINT; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANNEXIN A5; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MICELLES; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; POLYETHYLENE GLYCOLS; POLYMERS; PYRONES;

EID: 80053172509     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-9-42     Document Type: Article

References (42)

1. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ, Eisenberg BL, Ganz PA, Kramer BS, Kris MG. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of Clinical Oncology 2007, 25:146.
2. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic oncology 2008, 26:57. 10.1016/j.urolonc.2007.03.015, 18190833.
3. Nair KL, Jagadeeshan S, Nair SA, Kumar GSV. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. International Journal of Nanomedicine 2011, 6:1685-1697. 3184929, 21980233.
4. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine: Nanotechnology, Biology and Medicine 2007, 3:20-31.
5. Torchilin VP. Block copolymer micelles as a solution for drug delivery problems. Expert opinion on therapeutic patents 2005, 15:63-75.
6. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharmaceutical research 2007, 24:1-16.
7. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in Polymeric Micelles for Drug Delivery and Tumor Targeting. Nanomedicine: Nanotechnology, Biology and Medicine 2010,
8. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. Journal of Controlled Release 2005, 109:169-188. 10.1016/j.jconrel.2005.09.034, 16289422.
9. Tyrrell ZL, Shen Y, Radosz M. Fabrication of Micellar Nanoparticles for Drug Delivery Through the Self-Assembly of Block Copolymers. Progress in Polymer Science 2010,
10. Kim SY, Cho SH, Chu L, Lee YM. Biotin-Conjugated Block Copolymeric Nanoparticles as Tumor-Targeted Drug Delivery Systems. Macromolecular Research 2007, 15:646.
11. Kim SY, Lee YM, Baik DJ, Kang JS. Toxic characteristics of methoxy poly (ethylene glycol)/poly (epsilon-caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. Biomaterials 2003, 24:55. 10.1016/S0142-9612(02)00248-X, 12417178.
12. Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharmaceutical research 2002, 19:1424-1429. 10.1023/A:1020488012264, 12425458.
13. Weissig V, Whiteman KR, Torchilin VP. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharmaceutical research 1998, 15:1552-1556. 10.1023/A:1011951016118, 9794497.
14. Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. Journal of Controlled Release 2007, 118:7-17. 10.1016/j.jconrel.2006.11.028, 17241684.
15. Lin WJ, Chen YC, Lin CC, Chen CF, Chen JW. Characterization of pegylated copolymeric micelles and in vivo pharmacokinetics and biodistribution studies. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2006, 77:188-194.
16. Lin WJ, Juang LW, Lin CC. Stability and release performance of a series of pegylated copolymeric micelles. Pharmaceutical research 2003, 20:668-673. 10.1023/A:1023215320026, 12739777.
17. Lin WJ, Juang LW, Wang CL, Chen YC, Lin CC, Chang KL. Pegylated Polyester Polymeric Micelles as a Nano-carrier: Synthesis, Characterization, Degradation, and Biodistribution. Journal of Experimental & Clinical Medicine 2010, 2:4-10. 10.1016/S1878-3317(10)60002-2, 3175409, 21941688.
18. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. British journal of cancer 2005, 92:1240-1246. 10.1038/sj.bjc.6602479, 2361981, 15785749.
19. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clinical cancer research 2004, 10:3708. 10.1158/1078-0432.CCR-03-0655, 15173077.
20. Le Garrec D, Gori S, Luo L, Lessard D, Smith DC, Yessine MA, Ranger M, Leroux JC. Poly (N-vinylpyrrolidone)-block-poly (D, L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. Journal of Controlled Release 2004, 99:83-101. 10.1016/j.jconrel.2004.06.018, 15342183.
21. Liu J, Zeng F, Allen C. In vivo fate of unimers and micelles of a poly (ethylene glycol)-block-poly (caprolactone) copolymer in mice following intravenous administration. European Journal of Pharmaceutics and Biopharmaceutics 2007, 65:309-319. 10.1016/j.ejpb.2006.11.010, 17257817.
22. Wang F, Bronich TK, Kabanov AV, Rauh RD, Roovers J. Synthesis and Characterization of Star Poly (-caprolactone)-b-Poly (ethylene glycol) and Poly (l-lactide)-b-Poly (ethylene glycol) Copolymers: Evaluation as Drug Delivery Carriers. Bioconjugate chemistry 2008, 19:1423-1429. 10.1021/bc7004285, 2711207, 18564869.
23. Wang YC, Tang LY, Sun TM, Li CH, Xiong MH, Wang J. Self-Assembled Micelles of Biodegradable Triblock Copolymers Based on Poly (ethyl ethylene phosphate) and Poly (-caprolactone) as Drug Carriers. Biomacromolecules 2007, 9:388-395.
24. Shuai X, Ai H, Nasongkla N, Kim S, Gao J. Micellar carriers based on block copolymers of poly (-caprolactone) and poly (ethylene glycol) for doxorubicin delivery. Journal of Controlled Release 2004, 98:415-426. 10.1016/j.jconrel.2004.06.003, 15312997.
25. Yang Y, Hua C, Dong CM. Synthesis, Self-Assembly, and In Vitro Doxorubicin Release Behavior of Dendron-like/Linear/Dendron-like Poly (-caprolactone)-b-Poly (ethylene glycol)-b-Poly (-caprolactone) Triblock Copolymers. Biomacromolecules 2009, 10:2310-2318. 10.1021/bm900497z, 19618927.
26. Blum RH, Carter SK. Adriamycin. Annals of Internal Medicine 1974, 80:249-259.
27. Al-Shabanah OA, El-Kashef HA, Badary OA, Al-Bekairi AM, Elmazar M. Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. Pharmacological Research 2000, 41:31-37. 10.1006/phrs.1999.0568, 10600267.
28. Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer chemotherapy and pharmacology 1990, 27:13-19. 10.1007/BF00689270, 2245488.
29. Rahman A, Joher A, Neefe JR. Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. British journal of cancer 1986, 54:401-408. 10.1038/bjc.1986.190, 2001633, 3489480.
30. Chang YC, Chu I. Methoxy poly (ethylene glycol)-b-poly (valerolactone) diblock polymeric micelles for enhanced encapsulation and protection of camptothecin. European Polymer Journal 2008, 44:3922-3930.
31. Lee H, Zeng F, Dunne M, Allen C. Methoxy poly (ethylene glycol)-block-poly (-valerolactone) copolymer micelles for formulation of hydrophobic drugs. Biomacromolecules 2005, 6:3119-3128. 10.1021/bm050451h, 16283736.
32. Lin WJ, Wang CL, Juang LW. Characterization and comparison of diblock and triblock amphiphilic copolymers of poly (valerolactone). Journal of Applied Polymer Science 2006, 100:1836-1841.
33. Gillies ER, Fréchet JMJ. pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjugate Chem 2005, 16:361-368.
34. Tang R, Ji W, Wang C. Amphiphilic Block Copolymers Bearing Ortho Ester Side Chains: pH Dependent Hydrolysis and Self Assembly in Water. Macromolecular bioscience 2009, 10:192-201.
35. Krishnan A, Hariharan R, Nair SA, Pillai MR. Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS) 1. Biochemical pharmacology 2008, 75:1924-1934. 10.1016/j.bcp.2008.02.013, 18371935.
36. DiPaola RS. To Arrest or Not To G2-M Cell-Cycle Arrest. Clinical cancer research 2002, 8:3311.
37. Barlogie B, Drewinko B, Johnston DA, Freireich EJ. The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line. Cancer Research 1976, 36:1975.
38. O'Loughlin C, Heenan M, Coyle S, Clynes M. Altered cell cycle response of drug-resistant lung carcinoma cells to doxorubicin. European Journal of Cancer 2000, 36:1149-1160. 10.1016/S0959-8049(00)00071-X, 10854949.
39. Upadhyay KK, Bhatt AN, Mishra AK, Dwarakanath BS, Jain S, Schatz C, Le Meins JF, Farooque A, Chandraiah G, Jain AK. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly ([gamma]-benzyl l-glutamate)-b-hyaluronan polymersomes. Biomaterials 2010, 31:2882-2892. 10.1016/j.biomaterials.2009.12.043, 20053435.
40. Danhier F, Lecouturier N, Vroman B, Jér me C, Marchand-Brynaert J, Feron O, Préat V. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. Journal of Controlled Release 2009, 133:11-17. 10.1016/j.jconrel.2008.09.086, 18950666.
41. Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, Fahmy TM. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine: Nanotechnology, Biology and Medicine 2009, 5:410-418.
42. Hu Y, Zhang L, Cao Y, Ge H, Jiang X, Yang C. Degradation Behavior of Poly (-caprolactone)-b-poly (ethylene glycol)-b-poly (-caprolactone) Micelles in Aqueous Solution. Biomacromolecules 2004, 5:1756-1762. 10.1021/bm049845j, 15360284.